Craft

Kyowa Kirin

Stock Price

$17

2024-06-26

Market Capitalization

$9.2 B

2024-06-26

Revenue

¥442.2 B

FY, 2023

Kyowa Kirin Summary

Company Summary

Overview
Kyowa Kirin (formerly Kyowa Hakko Kirin) is a pharmaceutical company focused on the areas of oncology, nephrology, immunology, and the central nervous system. It specializes in therapeutic antibodies, small molecule drugs, therapeutic nucleic acids, and regenerative medicine. The company was formed as a result of a merger between Kyowa Hakko and Kirin Pharma.
Type
Public
Status
Active
Founded
2008
HQ
Tokyo, JP | view all locations
Website
https://www.kyowakirin.com
Cybersecurity rating
Sectors

Key People

  • Shintaro Hasegawa

    Shintaro Hasegawa, President and Chief Executive Officer

    • Yutaka Osawa

      Yutaka Osawa, Representative Director Executive Vice President

      LocationsView all

      31 locations detected

      • Tokyo, Tokyo HQ

        Japan

        Otemachi Financial City Grand Cube, 1-9-2 Otemachi

      • Bedminster, NJ

        United States

        135 Route 202/206, Suite 6

      • Princeton, NJ

        United States

        212 Carnegie Center Dr Suite 400

      • San Diego, CA

        United States

        9420 Athena Cir, La Jolla

      • Sydney, NSW

        Australia

        68 York St

      • Shanghai, Shang Hai Shi

        China

        970 Longdong Road,Pilot Free Trade Zone

      and 25 others

      Kyowa Kirin Financials

      Summary Financials

      Revenue (FY, 2023)
      ¥442.2B
      Gross profit (FY, 2023)
      ¥368.9B
      Net income (FY, 2023)
      ¥81.2B
      Cash (FY, 2023)
      ¥403.1B
      EBIT (FY, 2023)
      ¥92.6B
      Enterprise value
      ($393.9B)

      Footer menu